Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6095500 | 0.98 | L3MBTL1 (0.56) | L3MBTL1HTTMEN1KMT2AADRA1A | |
| Hydrochloric Acid SCHEMBL4304760 | 0.96 | L3MBTL1 (0.54) | L3MBTL1HTTMEN1KMT2AADRA1A | |
| SCHEMBL6247191 | 0.77 | KDM4E (0.41) | L3MBTL1HTTMEN1KMT2AKDM4E | |
| SCHEMBL14744698 | 0.74 | HTT (0.47) | L3MBTL1HTTMEN1KMT2AADRA1A | |
| Hydrochloric Acid SCHEMBL31417032 | 0.72 | HTT (0.46) | L3MBTL1HTTMEN1KMT2AADRA1A | |
| SCHEMBL13120889 | 0.72 | TYMP (0.50) | L3MBTL1HTTMEN1KMT2AKDM4E | |
| SCHEMBL6024268 | 0.70 | NR1H2 (0.60) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL2329966 | 0.68 | HTT (1.00) | L3MBTL1HTTMEN1KMT2AMAPT | |
| SCHEMBL31146250 | 0.66 | MAPT (0.40) | L3MBTL1HTTMEN1KMT2AADRA1A | |
| SCHEMBL17495146 | 0.66 | HTT (0.44) | L3MBTL1HTTMEN1KMT2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513424-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120258959-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2012-10-11 | — | — | US | disclosed |
| US-8232404-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110245227-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| EP-2170864-B1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-14 | — | — | EP | disclosed |
| US-8003796-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2170864-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-22 | — | — | US | disclosed |
| WO-2009012275-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
| US-7220758-B2 | Ether substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-22 | — | — | US | disclosed |
| US-4672125-A | Chlorination of β-methylpyridine compounds | THE DOW CHEMICAL COMPANY (US) | 1987-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258959-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR65, GPR27 | L3MBTL1 4494/4885HTT 3908/4885MEN1 3600/4885 |
| US-20110245227-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR65, GPR27 | L3MBTL1 4494/4885HTT 3908/4885MEN1 3600/4885 |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR65, GPR27 | L3MBTL1 4498/4885HTT 3925/4885MEN1 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.